Literature DB >> 9790633

A long-term follow-up of choroidal osteoma.

G W Aylward1, T S Chang, S E Pautler, J D Gass.   

Abstract

OBJECTIVE: To provide long-term follow-up information on a large series of patients with choroidal osteoma.
METHODS: Review of patients with a diagnosis of choroidal osteoma who had been examined at the Bascom Palmer Eye Institute, Miami, Fla, or known to one of us (J.D.M.G.). Information was obtained from hospital medical records or by a questionnaire sent to referring ophthalmologists. Life-table analysis was used to study the loss of vision and development of choroidal neovascularization.
RESULTS: We followed up 36 patients, 31 (89%) were female, mean age, 21 years (range, 5-54 years) for a mean of 10 years (range, 2-22 years). Growth was observed for 9 (41%) of 22 well-documented osteomas. The probability of loss of visual acuity to 20/200 or worse was 58% by 10 years and 62% by 20 years. The probability of developing choroidal neovascularization was 47% by 10 years and 56% by 20 years. Successful treatment of the choroidal neovascularization with laser photocoagulation was performed for 5 (25%) of 20 patients.
CONCLUSIONS: Most patients with choroidal osteomas maintain good vision in at least 1 eye, but they have a high risk of developing choroidal neovascularization. When this occurs, only a minority can be successfully treated with laser photocoagulation.

Entities:  

Mesh:

Year:  1998        PMID: 9790633     DOI: 10.1001/archopht.116.10.1337

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  38 in total

1.  A case of choroidal osteoma with subsequent laser induced decalcification.

Authors:  G Gurelik; Y Lonneville; N Safak; S C Ozdek; B Hasanreisoglu
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization.

Authors:  Farhad Fazel Najafabadi; Seyyed Moien Hendimarjan; Yasaman Zarrin; Mohammadreza Fazel Najafabadi
Journal:  J Ophthalmic Vis Res       Date:  2015 Oct-Dec

3.  Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab.

Authors:  Andrea Saitta; Michele Nicolai; Piergiorgio Neri; Michele Reibaldi; Alfonso Giovannini; Cesare Mariotti
Journal:  Int Ophthalmol       Date:  2015-03-12       Impact factor: 2.031

4.  [Choroidal neovascularisation in a patient with choroidal osteoma visualized by OCT angiography].

Authors:  N Mihailovic; M Alnawaiseh; R-L Merté; N Eter
Journal:  Ophthalmologe       Date:  2017-09       Impact factor: 1.059

5.  [Manifestation of bilateral choroidal osteoma in childhood. Progressive myopia due to staphyloma posticum].

Authors:  J Heichel; T Bredehorn-Mayr; U Stuhlträger; K S Kunert; M Jäger; B Lorenz
Journal:  Ophthalmologe       Date:  2016-02       Impact factor: 1.059

6.  Bone Remodeling in Choroidal Osteoma Monitored by Fundus Photography and Spectral-Domain Optical Coherence Tomography.

Authors:  Tengku Ain Kamalden; Gopal Lingam; Gangadhara Sundar
Journal:  Ocul Oncol Pathol       Date:  2014-06-20

7.  [Choroidal osteoma].

Authors:  N Negraszus
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

8.  Choroidal osteoma with CNVM - Successful treatment with intravitreal Bevacizumab.

Authors:  Guruprasad S Ayachit; Neeraj Pandey; Vandana Dwivedi
Journal:  Saudi J Ophthalmol       Date:  2010-11-13

9.  Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin).

Authors:  Hamid Ahmadieh; Nasser Vafi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-25       Impact factor: 3.117

10.  Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma.

Authors:  V P Papastefanou; M Pefkianaki; L Al Harby; A K Arora; V M L Cohen; R M Andrews; M S Sagoo
Journal:  Eye (Lond)       Date:  2016-04-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.